136 related articles for article (PubMed ID: 36558827)
1. Development of Monoclonal Antibody to Specifically Recognize VP0 but Not VP4 and VP2 of Foot-and-Mouth Disease Virus.
Park SY; Jin JS; Kim D; Kim JY; Park SH; Park JH; Park CK; Ko YJ
Pathogens; 2022 Dec; 11(12):. PubMed ID: 36558827
[TBL] [Abstract][Full Text] [Related]
2. Engineering Responses to Amino Acid Substitutions in the VP0- and VP3-Coding Regions of PanAsia-1 Strains of Foot-and-Mouth Disease Virus Serotype O.
Bai XW; Bao HF; Li PH; Ma XQ; Sun P; Bai QF; Zhang M; Yuan H; Chen DD; Li K; Chen YL; Cao YM; Fu YF; Zhang J; Li D; Lu ZJ; Liu ZX; Luo JX
J Virol; 2019 Apr; 93(7):. PubMed ID: 30700601
[TBL] [Abstract][Full Text] [Related]
3. Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: the structure of empty capsids of foot-and-mouth disease virus.
Curry S; Fry E; Blakemore W; Abu-Ghazaleh R; Jackson T; King A; Lea S; Newman J; Stuart D
J Virol; 1997 Dec; 71(12):9743-52. PubMed ID: 9371640
[TBL] [Abstract][Full Text] [Related]
4. Membrane Interactions and Uncoating of Aichi Virus, a Picornavirus That Lacks a VP4.
Kelly JT; Swanson J; Newman J; Groppelli E; Stonehouse NJ; Tuthill TJ
J Virol; 2022 Apr; 96(7):e0008222. PubMed ID: 35293769
[TBL] [Abstract][Full Text] [Related]
5. Effects of mutations in the VP2/VP4 cleavage site of Swine vesicular disease virus on RNA encapsidation and viral infectivity.
Rebel JM; Leendertse CH; Dekker A; Moormann RJ
Arch Virol; 2003 Sep; 148(9):1747-56. PubMed ID: 14505087
[TBL] [Abstract][Full Text] [Related]
6. Processing of structural polypeptides of infectious flacherie virus of the silkworm, Bombyx mori: VP1 and VP4 are derived from VP0.
Choi HK; Sasaki T; Tomita T; Kobayashi M; Kawase S
J Invertebr Pathol; 1992 Sep; 60(2):113-6. PubMed ID: 1401988
[TBL] [Abstract][Full Text] [Related]
7. Determining the epitope dominance on the capsid of a serotype SAT2 foot-and-mouth disease virus by mutational analyses.
Opperman PA; Rotherham LS; Esterhuysen J; Charleston B; Juleff N; Capozzo AV; Theron J; Maree FF
J Virol; 2014 Aug; 88(15):8307-18. PubMed ID: 24829347
[TBL] [Abstract][Full Text] [Related]
8. Expression of virus-like particles (VLPs) of foot-and-mouth disease virus (FMDV) using Saccharomyces cerevisiae.
Le NMT; So KK; Chun J; Kim DH
Appl Microbiol Biotechnol; 2024 Dec; 108(1):81. PubMed ID: 38194136
[TBL] [Abstract][Full Text] [Related]
9. The N-terminal region (VP4) of the foot-and-mouth disease capsid precursor (P1-2A) is not required during its synthesis to allow subsequent processing by the 3C protease.
Kristensen T; Normann P; Belsham GJ
Virology; 2022 May; 570():29-34. PubMed ID: 35364457
[TBL] [Abstract][Full Text] [Related]
10. Amino acid substitutions in the poliovirus maturation cleavage site affect assembly and result in accumulation of provirions.
Ansardi DC; Morrow CD
J Virol; 1995 Mar; 69(3):1540-7. PubMed ID: 7853487
[TBL] [Abstract][Full Text] [Related]
11. Viral RNA modulates the acid sensitivity of foot-and-mouth disease virus capsids.
Curry S; Abrams CC; Fry E; Crowther JC; Belsham GJ; Stuart DI; King AM
J Virol; 1995 Jan; 69(1):430-8. PubMed ID: 7983739
[TBL] [Abstract][Full Text] [Related]
12. Poliovirus mutants at histidine 195 of VP2 do not cleave VP0 into VP2 and VP4.
Hindiyeh M; Li QH; Basavappa R; Hogle JM; Chow M
J Virol; 1999 Nov; 73(11):9072-9. PubMed ID: 10516013
[TBL] [Abstract][Full Text] [Related]
13. Two Cross-Protective Antigen Sites on Foot-and-Mouth Disease Virus Serotype O Structurally Revealed by Broadly Neutralizing Antibodies from Cattle.
Li K; He Y; Wang L; Li P; Wang S; Sun P; Bao H; Cao Y; Liu X; Zhu G; Song Y; Bai X; Ma X; Fu Y; Yuan H; Zhang J; Wang J; Chen Y; Li D; Lou Z; Liu Z; Lu Z
J Virol; 2021 Oct; 95(21):e0088121. PubMed ID: 34406868
[TBL] [Abstract][Full Text] [Related]
14. Isolation of capsid proteins of foot-and-mouth disease virus by chromatofocusing.
Murdin AD; Doel TR; Spier RE
J Virol Methods; 1983 Oct; 7(4):207-16. PubMed ID: 6317707
[TBL] [Abstract][Full Text] [Related]
15. Identification of a serotype-independent linear epitope of foot-and-mouth disease virus.
Yang B; Wang M; Liu W; Xu Z; Wang H; Yang D; Ma W; Zhou G; Yu L
Arch Virol; 2017 Dec; 162(12):3875-3880. PubMed ID: 28884236
[TBL] [Abstract][Full Text] [Related]
16. Engineering viable foot-and-mouth disease viruses with increased acid stability facilitate the development of improved vaccines.
Yuan H; Li P; Bao H; Sun P; Bai X; Bai Q; Li N; Ma X; Cao Y; Fu Y; Li K; Zhang J; Li D; Chen Y; Zhang J; Lu Z; Liu Z
Appl Microbiol Biotechnol; 2020 Feb; 104(4):1683-1694. PubMed ID: 31900553
[TBL] [Abstract][Full Text] [Related]
17. Poly (rC) binding protein 2 interacts with VP0 and increases the replication of the foot-and-mouth disease virus.
Li D; Zhang J; Yang W; He Y; Ru Y; Fu S; Li L; Liu X; Zheng H
Cell Death Dis; 2019 Jul; 10(7):516. PubMed ID: 31273191
[TBL] [Abstract][Full Text] [Related]
18. Structural refinement and analysis of Mengo virus.
Krishnaswamy S; Rossmann MG
J Mol Biol; 1990 Feb; 211(4):803-44. PubMed ID: 2156078
[TBL] [Abstract][Full Text] [Related]
19. Generation of Antibodies against Foot-and-Mouth-Disease Virus Capsid Protein VP4 Using Hepatitis B Core VLPs as a Scaffold.
Swanson J; Fragkoudis R; Hawes PC; Newman J; Burman A; Panjwani A; Stonehouse NJ; Tuthill TJ
Life (Basel); 2021 Apr; 11(4):. PubMed ID: 33920339
[TBL] [Abstract][Full Text] [Related]
20. Identification of a conserved conformational epitope in the VP2 protein of foot-and-mouth disease virus.
Liu W; Yang B; Wang M; Liang W; Wang H; Yang D; Ma W; Zhou G; Yu L
Arch Virol; 2017 Jul; 162(7):1877-1885. PubMed ID: 28258408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
